Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.

CANCER drug co. Oxford Biomedica charts (OXB)     

apple - 25 Mar 2004 20:47

Chart.aspx?Provider=EODIntra&Code=OXB&Sidraw?scheme=Colourful&size=Medium&showVodraw?scheme=Colourful&showVolume=true&stdraw?scheme=Colourful&size=Medium&showVoChart.aspx?Provider=EODIntra&Code=OXB&SiChart.aspx?Provider=EODIntra&Code=OXB&Sidraw?scheme=Designer&size=Big&showVolumedraw?scheme=Designer&size=Big&showVolume


OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021


1704 - 02 Mar 2005 14:11 - 501 of 1451


Not very surprised at all the selling of the stock today
after the spike upwards this morning. Quite a few investors
may have bought into the stock at sub-20p levels a few
days ago and would have sold for a small profit and who
can blame them.

The Trovax results have been good and I am looking foward
to recieving the preliminary results. Now that the Troxax
results have been announced there should be quite a few
new positive articles in the financial press for the
next couple of weeks which should lead to the sp
continuing to move upwards.

Am I worried about the dip in the sp? You've gotta be
joking mate. I'm more worried about how Man Utd will be
able to turnaround the 1-0 deficit against AC Milan next
Wednesday.



accord - 02 Mar 2005 14:34 - 502 of 1451

theres alot of blue on the trades so it beats me that the sp is in the red.

Its a funny old game............

1704 - 02 Mar 2005 15:27 - 503 of 1451


I'm not expecting the dip in the sp to last
longer than a day. Hopefully there should be
some positive comments in the newspapers
tommorrow and we are expecting the preliminary
results soon which should keep OXB in the
headlines for a few weeks.

I noticed before the recent rises that 'buys'
were outnumbering 'sells' and the sp was
still falling. It certainly is a funny old game.

Usually I like to see the colour red but not
when OXB is concerned.

Madison - 02 Mar 2005 17:12 - 504 of 1451

A few large buys at end of day above the offer, and a mainly blue afternoon. Ought to be back up in the morning. But then what do I know!

1704 - 02 Mar 2005 18:14 - 505 of 1451


The last trade today was a 'buy' of 500,000.
I look foward to seeing some more similar
size 'buys' over the next few days.

Panicking over the drop in the sp today?
Me nah! and nor is that investor by the
looks of things.

All the Best.

pachandl - 02 Mar 2005 20:42 - 506 of 1451

Apologies for this but I thought that I would post an update from DD on ADV as he had the gumption to actually find out a bit more:

DoobyDave - 2 Mar'05 - 14:19 - 4208 of 4280


With regard to my earlier post 4138 concerning the disease staging of the Trovax colorectal trial patients, I rang up the company a few minutes ago to clarify matters.

By way of reminder, five year survival rates by stage quoted by the Royal College of Surgeons are

Dukes' A - 85%
Dukes' B - 67%
Dukes' C - 37% (combines C1 and C2 stages)
Dukes' D (sometimes referred to as stage 4) - no figure quoted but approximates to zero over 5 years.

It turns out that the trial patients all had Duke's D (Stage 4) disease, with liver or other solid organ metastases (secondaries). The outlook for this group of patients is normally assured death within a year, often within a few weeks (there is huge variability).

Hence, these results ARE truly excellent, despite it being too early to be banking on long term survival.

Please note there is now a detailed presentation on the Oxford Biomedica website, Please especially note slide 10, which compares the chemotherapy agent alone to chemo plus Trovax. Combination with either agent increases clinical response rate by 50%. It also beats all other immunotherapy trials to date.

The other slide of major interest is slide 15, on anticipated newsflow.

The company confirms that there remains a possibility that further Trovax doses may further enhance survival, but this is purely speculative.
DD

pachandl - 02 Mar 2005 20:42 - 507 of 1451

[deleted - my mistake]

apple - 04 Mar 2005 09:45 - 508 of 1451

20.75p Down another 4.6%

If it goes under 20p then I'll increase my stake again.


accord - 04 Mar 2005 09:47 - 509 of 1451

Oxford Biomedica PLC
04 March 2005


FOR IMMEDIATE RELEASE 4 MARCH 2005

OXFORD BIOMEDICA ANNOUNCES BOARD APPOINTMENT



Oxford, UK - 4 March 2005: Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, today announces that Nick Woolf has been promoted to the Board
as an executive director. He will maintain his title of Senior Vice President
for Corporate Strategy. His primary responsibilities include corporate finance,
M&A evaluation and corporate communications as well as an important role,
jointly with Peter Nolan, in business development and deal negotiation.



Prior to joining Oxford BioMedica in 2002, Nick spent eight years as a top-rated
biotechnology and pharmaceutical analyst. Nick has been involved in all aspects
of company financing, ranging from IPOs to major corporate deals. He served as
Director and Head of European Biotechnology Research at ABN AMRO, and was
previously with Robertson Stephens International, Nomura and SBC Warburg. Nick
holds an MA from Oxford University in Chemistry.



Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive of
Oxford BioMedica, said: 'Nick has contributed at a very high level to all
corporate activities and has been instrumental in raising the Company's profile
in the industry and the investment community. We are delighted to welcome him to
the Board.'



-Ends-

middleman - 08 Mar 2005 11:28 - 510 of 1451

L2 anyone? TIA.

apple - 14 Mar 2005 10:46 - 511 of 1451

Bought a few more again this morning.

A moderate amount this time because there may be a slightly better opportunity soon.

apple - 14 Mar 2005 14:57 - 512 of 1451

Seems to be some more interest in this 1 today, I wonder why?

Madison - 14 Mar 2005 22:17 - 513 of 1451


RNS Number:7109J
Oxford Biomedica PLC
14 March 2005


FOR IMMEDIATE RELEASE 14 MARCH 2005


OXFORD BIOMEDICA DEMONSTRATES THAT ITS LENTIVECTOR(R) TECHNOLOGY IS THE SYSTEM
OF CHOICE FOR RNAI APPLICATIONS


Oxford, UK - 14 March 2005: Oxford BioMedica (LSE:OXB.L), the leading gene
therapy company, announced today the publication, in the journal Nature
Medicine, of a paper demonstrating efficacy of the Company's LentiVector
technology in an animal model of inherited (familial) amyotrophic lateral
sclerosis (ALS) or motor neuron disease. The paper describes the delivery, by
the LentiVector technology, of a specific RNAi molecule that shuts down the gene
that causes the disease.


Familial ALS is caused by a series of mutations in a gene called SOD1. The
disease represents about 2% of the total ALS cases. These mutations cause the
SOD1 gene to acquire a new function that destroys motor neurons. The neurons die
and the patient loses muscle control in a similar way to the more common
acquired ALS or Lou Gehrig's disease. Patients generally die from respiratory
failure because they are unable to control their diaphragm muscle. Switching off
the gene stops the development of the disease but the challenge so far has been
to achieve that goal.


RNAi is a new technology that uses small RNA molecules to switch off any gene of
choice. It has been adopted widely by the pharmaceutical industry as a means of
identifying genes with a causative relationship to specific diseases. The
Company's LentiVector technology is perfectly suited to deliver these molecules
and this is what has been reported in the Nature Medicine paper. A LentiVector
has been used to deliver a highly specific RNAi molecule to a selection of motor
neurons in a mouse that has the mutated SOD1 gene. The data show that delivery
was very efficient and there was a 100% extension of the time to onset of the
disease as well as a 70% increase in survival.


Commenting on the results the Company's CEO, Prof. Alan Kingsman, said: "These
data show that our LentiVector technology is the system of choice for the
genetic delivery of RNAi molecules. This is a particularly powerful illustration
of the point and is assisting us with our ongoing out-licensing of the
LentiVector technology for drug discovery and transgenic applications. We have
already completed four such deals and we have five further term sheets under
discussion."


From a rare visit to the other side, where there is some optimism over the last sentence above. Cheers, Madison.

robstuff - 16 Mar 2005 09:05 - 514 of 1451

here we go again, trading volumes suddenly risen, mostly Buys. Back to 28? The news of course is excellent but we all know that unless they announce a definite cure for all cancers, then news doesn't budge Oxb. No, it's prob more takeover speculation. The co is worth a lot more by the mth as more data is released.

mcp2 - 16 Mar 2005 09:19 - 515 of 1451

Hi guys,

Perhaps it's this:

http://www.oxfordbiomedica.co.uk/news/2005-ob-08.htm

That's been causing some speculative interest in the last couple of days.

I shall try (if at all possible) to be tuned in to listen to the webcast.

Cheers,

mcp2.

tbrooking66 - 16 Mar 2005 14:37 - 516 of 1451

This is from the press summary from todays Express:

SHARE WHISPER: OXFORD BIOMEDICA (talk of a potential partnership deal with Johnson & Johnson, which could be mulling a takeover)

Also just listened to the webcast and all that talk of studies takes me back to my uni days. The main subjects covered were the various products they are developing. The work they are doing does sound impressive to me and seems to be coming along nicely. Not sure how this should affect the share price but everything appears to be ticking along nicely.

Oakapples142 - 16 Mar 2005 14:50 - 517 of 1451


Thanks nice research - reckon we are bound for "Route 66"

tbrooking66 - 16 Mar 2005 17:59 - 518 of 1451

the webcast will be on their site for the next month or so if anyone wants to have a listen. the speech was about half an hour long.

apple - 17 Mar 2005 11:06 - 519 of 1451

Thanks tbrooking66

How nice OXB UP yet again!

I seem to have timed it right again, on Monday.

Oakapples142 - 17 Mar 2005 12:00 - 520 of 1451

Results on Mon 21st March - Licence announcement to coincide would be nice and IMHO expected.
Register now or login to post to this thread.